Browsing by Author "S. Chakravorty"

Now showing 1 - 5 of 5

Dextrocardia with myocardial infarction
(Indian Medical Association, 1995) S. Chakravorty; P.C. Sarma; B.V. Agrawal
[No abstract available]
Uttar pradesh association of physicians of India position statement: Betel quid (paan) and diabetes
(Journal of Association of Physicians of India, 2018) Yatan Pal Singh Balhara; Sanjay Kalra; Sarita Bajaj; Pooja Patnaik Kuppili; D. Himanshu; Veerendra Atam; Kauser Usman; Veerendra Singh; Shyam Chand Chaudhary; S. Chakravorty; Anupam Wakhlu; Jalees Fatma; Sanjay Tandon; Anuj Maheshwari; Abha Gupta; Anjum Parvez; Jaya Chakravarty; R.R. Chaudhary; A.K. Singh; K.K. Sawlani; Manoj Mathur; N.K. Soni; Om Kumari Gupta; Madhukar Rai; Sudhir Agarwal
Betel quid (paan) chewing is common in India, especially in Uttar Pradesh. Betel quid has multifaceted relationship with health, including metabolic and psychosocial health. The current recommendations have been released keeping in view the public health and clinical importance of this addictive behavior. The objective of this document is to offer clinical guidance for screening, diagnosis and management of co-occurring betel quid chewing among persons with Diabetes Mellitus (DM). The document aims to provide education and guidance to clinicians engaged in care and management of persons with DM, and improve access to treatment for co-occurring betel quid chewing among persons with DM. The current recommendation grades are based on published evidence, and categorized as strong, intermediate, weak and no evidence. The strength of these recommendations is based on the level of evidence. © 2018, Journal of Association of Physicians of India. All rights reserved.
Uttar Pradesh Association of Physicians of India Position Statement: Betel Quid (Paan) and Diabetes
(NLM (Medline), 2018) Yatan Pal Singh Balhara; Sanjay Kalra; Sarita Bajaj; Pooja Patnaik Kuppili; D. Himanshu; Veerendra Atam; Kauser Usman; Kauser Usman; Veerendra Singh; Shyam Chand Chaudhary; S. Chakravorty; Anupam Wakhlu; Jalees Fatma; Sanjay Tandon; Anuj Maheshwari; Abha Gupta; Anjum Parvez; Jaya Chakravarty; R.R. Chaudhary; A.K. Singh; K.K. Sawlani; Manoj Mathur; N.K. Soni; Om Kumari Gupta; Madhukar Gupta; Sudhir Agarwal
Betel quid (paan) chewing is common in India, especially in Uttar Pradesh. Betel quid has multifaceted relationship with health, including metabolic and psychosocial health. The current recommendations have been released keeping in view the public health and clinical importance of this addictive behavior. The objective of this document is to offer clinical guidance for screening, diagnosis and management of co-occurring betel quid chewing among persons with Diabetes Mellitus (DM). The document aims to provide education and guidance to clinicians engaged in care and management of persons with DM, and improve access to treatment for co-occurring betel quid chewing among persons with DM. The current recommendation grades are based on published evidence, and categorized as strong, intermediate, weak and no evidence. The strength of these recommendations is based on the level of evidence. © Journal of the Association of Physicians of India 2011.
Uttar Pradesh association of physicians of India position statement: Tobacco use and metabolic syndrome
(Journal of Association of Physicians of India, 2017) Yatan Pal Singh Balhara; Sanjay Kalra; Sarita Bajaj; Pooja Patnaik Kuppili; D. Himanshu; Veerendra Atam; Kauser Usman; Veerendra Singh; Shyam Chand Chaudhary; S. Chakravorty; Anupam Wakhlu; Jalees Fatma; Sanjay Tandon; Anuj Maheshwari; Abha Gupta; Anjum Parvez; Jaya Chakravarty; R.R. Chaudhary; A.K. Singh; K.K. Sawlani; Manoj Mathur; N.K. Soni; Om Kumari Gupta; Madhukar Rai; Sudhir Agarwal
Tobacco use is one of the main preventable causes of mortality and morbidity worldwide. The global disease burden due to tobacco use is huge with projected mortality of eight million lives per year by 2030. Metabolic syndrome (MS) is defined as a constellation of cardiovascular and endocrine risk factors such as insulin resistance, obesity, raised blood pressure, and abnormal lipid profile. The relationship between tobacco use and MS has been well established. Also, the causal association between tobacco use and development of individual components of MS is well established. The Uttar Pradesh Association of Physicians of India (UP API) has drafted this position statement on managing tobacco use among persons with or at risk of developing Metabolic Syndrome (MS). This position statement presents evidence-based recommendations as described below. Scope and purpose The objective of this position statement is to offer clinical recommendations for screening, diagnosis and management of tobacco use among persons with or at risk of developing Metabolic Syndrome (MS). The purpose of this document is to aid in identification and treatment of maladaptive patterns of tobacco use i.e. tobacco use disorder (tobacco dependence, harmful use, abuse) in person with or at risk of developing MS. Intended Audience The position statement is targeted at the clinicians engaged in care and management of person with or at risk of developing Metabolic Syndrome (MS). This might also be of relevance to the policy makers considering the public health burden of both MS and tobacco use disorders. © 2017, Journal of Association of Physicians of India. All rights reserved.
Vaccination saves lives: a real-time study of patients with chronic diseases and severe COVID-19 infection
(Oxford University Press, 2023) A. Mukherjee; G. Kumar; A. Turuk; A. Bhalla; T.C. Bingi; P. Bhardwaj; T.D. Baruah; S. Mukherjee; A. Talukdar; Y. Ray; M. John; J.R. Khambholja; A.H. Patel; S. Bhuniya; R. Joshi; G.R. Menon; D. Sahu; V.V. Rao; B. Bhargava; S. Panda; P. Mishra; Y. Panchal; L.K. Sharma; A. Agarwal; G.D. Puri; V. Suri; K. Singla; R. Mesipogu; V.S. Aedula; M.A. Mohiuddin; D. Kumar; S. Saurabh; S. Misra; P.K. Kannauje; A. Kumar; A. Shukla; A. Pal; S. Chakraborty; M. Dutta; T. Mondal; S. Chakravorty; B. Bhattacharjee; S.R. Paul; D. Majumder; S. Chatterjee; A. Abraham; D. Varghese; M. Thomas; N. Shah; M. Patel; S. Madan; A. Desai; M.L. Kala Yadhav; R. Madhumathi; G.S. Chetna; U.K. Ojha; R.R. Jha; A. Kumar; A. Pathak; A. Sharma; M. Purohit; L. Sarangi; M. Rath; A.D. Shah; L. Kumar; P. Patel; N. Dulhani; S. Dube; J. Shrivastava; A. Mittal; L. Patnaik; J.P. Sahoo; S. Sharma; V.K. Katyal; A. Katyal; N. Yadav; R. Upadhyay; S. Srivastava; A. Srivastava; N.N. Suthar; N.M. Shah; K. Rajvansh; H. Purohit; P.R. Mohapatra; M.K. Panigrahi; S. Saigal; A. Khurana; M. Panchal; M. Anderpa; D. Patel; V. Salgar; S. Algur; R. Choudhury; M. Rao; D. Nithya; B.K. Gupta; B. Kumar; J. Gupta; S. Bhandari; A. Agrawal; M. Shameem; N. Fatima; S. Pala; V. Nongpiur; S. Chatterji; S. Mukherjee; S.K. Shivnitwar; S. Tripathy; P. Lokhande; H. Dandu; A. Gupta; V. Kumar; N. Sharma; R. Vohra; A. Paliwal; M. Pavan Kumar; A. Bikshapathi Rao; N. Kikon; R. Kikon; K. Manohar; Y. Sathyanarayana Raju; A. Madharia; J. Chakravarty; M. Chaubey; R.K. Bandaru; M. Ali Mirza; S. Kataria; P. Sharma; S. Ghosh; A. Hazra
Objectives: This study aims to describe the demographic and clinical profile and ascertain the determinants of outcome among hospitalized coronavirus disease 2019 (COVID-19) adult patients enrolled in the National Clinical Registry for COVID-19 (NCRC). Methods: NCRC is an on-going data collection platform operational in 42 hospitals across India. Data of hospitalized COVID-19 patients enrolled in NCRC between 1st September 2020 to 26th October 2021 were examined. Results: Analysis of 29 509 hospitalized, adult COVID-19 patients [mean (SD) age: 51.1 (16.2) year; male: 18 752 (63.6%)] showed that 15 678 (53.1%) had at least one comorbidity. Among 25 715 (87.1%) symptomatic patients, fever was the commonest symptom (72.3%) followed by shortness of breath (48.9%) and dry cough (45.5%). In-hospital mortality was 14.5% (n = 3957). Adjusted odds of dying were significantly higher in age group ≥60 years, males, with diabetes, chronic kidney diseases, chronic liver disease, malignancy and tuberculosis, presenting with dyspnoea and neurological symptoms. WHO ordinal scale 4 or above at admission carried the highest odds of dying [5.6 (95% CI: 4.6–7.0)]. Patients receiving one [OR: 0.5 (95% CI: 0.4–0.7)] or two doses of anti-SARS CoV-2 vaccine [OR: 0.4 (95% CI: 0.3–0.7)] were protected from in-hospital mortality. Conclusions: WHO ordinal scale at admission is the most important independent predictor for in-hospital death in COVID-19 patients. Anti-SARS-CoV2 vaccination provides significant protection against mortality. © The Author(s) 2022.